Injectables, Lasers and Korea's Medical-Beauty Tourism — {{date}}
South Korea’s medical tourism sector is undergoing a structural shift as foreign patient spending pivots from surgical procedures to dermatology and pharmacy services, with dermatology spending rising 64% year-over-year. Concurrently, regulatory scrutiny on counterfeit injectables has intensified globally following a CDC report on unapproved botulinum toxin in the US, while Korean manufacturers face diverging FDA approval paths.
Injectables, Lasers and Korea's Medical-Beauty Tourism — {{date}}
Top developments
Dermatology Overtakes Surgery in Foreign Spending
Recent data released in mid-October 2026 highlights a significant realignment in Korea’s medical tourism map. Foreign patient medical consumption in 2026 shows dermatology spending increased by 64%, while pharmacy visits surged by 196%, whereas the relative share of plastic surgery has declined. This shift reflects a growing preference among international visitors for non-invasive "K-beauty" treatments such as skin boosters and injectables over traditional surgical interventions.
Diverging FDA Paths for Korean Toxin Manufacturers
The competitive landscape for Korean botulinum toxin firms in the US has split sharply. Daewoong Pharmaceutical has secured a 14% share in the aesthetic toxin market and is pursuing therapeutic segment entry, while Hugel is transitioning to a direct sales model for its product Letybo. In contrast, Medytox remains stalled in the FDA approval process, having been unable to resubmit its application since 2024 due to insufficient data, a status that continues to impact its global standing.
Global Safety Alerts on Counterfeit Injectables
The US Centers for Disease Control and Prevention (CDC) issued a warning in early October 2026 after three women in Colorado developed severe adverse reactions—including numbness and muscle weakness—following injections with unapproved botulinum toxin. This incident underscores the ongoing risks of counterfeit injectables in the global supply chain, prompting stricter verification protocols for clinics treating international patients.
Local view
Regulatory Gaps in ECM Skin Boosters
During recent National Assembly audits, South Korean lawmakers highlighted critical regulatory gaps concerning ECM (Extracellular Matrix) skin boosters. Representative Park Ji-won pointed out that these products, often priced between 400,000 and 800,000 KRW per session, lack sufficient safety verification and are sometimes produced using materials from overseas cadaveric skin, raising significant safety concerns for foreign patients.
Industry Focus on Clinical Exchange
Korean pharmaceutical giant Medytox participated in the ICLAS Seoul 2026 conference, engaging with medical professionals from 21 countries to share clinical experiences regarding botulinum toxin and hyaluronic acid fillers. This initiative aims to strengthen global partnerships and demonstrate the clinical efficacy of Korean aesthetic products amidst growing international competition.
Context & numbers
Foreign Patient Statistics
According to the Korea Health Industry Development Institute (KHIDI), dermatology and plastic surgery accounted for 74% of all foreign patient visits in Korea as of late 2026. In 2025, these specialties recorded 1.55 million foreign patient visits, an 82.5% increase from the previous year, with total cosmetic surgery VAT refunds reaching 196.4 billion KRW.
Pricing and Market Trends
For US patients, Botox in Korea typically costs between $30 and $120 per area, with masseter treatments ranging from $80 to $250. The global dermal fillers and botulinum toxin market is projected to expand through 2035, driven by the rising demand for preventative aesthetics and minimally invasive treatments.
On the radar
- England's Aesthetic Regulation: New rules restricting who can perform cosmetic surgery procedures and imposing fines for non-compliance are set to take effect in England in 2027, potentially influencing global standards for clinic operations.
- CO2 Laser Market Growth: The global market for CO2 medical laser systems is forecast to grow through 2035, propelled by rising skin cancer cases and increased demand for outpatient aesthetic procedures.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
